{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:15:45Z","timestamp":1759482945285},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,11,29]],"date-time":"2009-11-29T00:00:00Z","timestamp":1259452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11892-009-0074-x","type":"journal-article","created":{"date-parts":[[2009,11,28]],"date-time":"2009-11-28T05:54:01Z","timestamp":1259387641000},"page":"453-459","source":"Crossref","is-referenced-by-count":9,"title":["Aldosterone and diabetic kidney disease"],"prefix":"10.1007","volume":"9","author":[{"given":"Young Sun","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Ryong","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,11,29]]},"reference":[{"issue":"4Pt2","key":"74_CR1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.ju.0000140445.82949.54","volume":"172","author":"H. Trachtman","year":"2004","unstructured":"Trachtman H, Weiser AC, Valderrama E, et al.: Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 2004, 172(4 Pt 2):1590\u20131594.","journal-title":"J Urol"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","volume":"63","author":"I. Feria","year":"2003","unstructured":"Feria I, Pichardo I, Juarez P, et al.: Therapeutic benefit of spironolactone in experimental cyclosporine A nephrotoxicity. Kidney Int 2003, 63:43\u201352.","journal-title":"Kidney Int"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"E.R. Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, et al.: Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63:1791\u20131800.","journal-title":"Kidney Int"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1254\/jphs.FMJ05003X3","volume":"100","author":"A. Nishiyama","year":"2006","unstructured":"Nishiyama A, Abe Y: Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 2006, 100:9\u201316.","journal-title":"J Pharmacol Sci"},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpneph0362","volume":"3","author":"L. Vecchio Del","year":"2007","unstructured":"Del Vecchio L, Procaccio M, Vigano S, Cusi D: Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007, 3:42\u201349.","journal-title":"Nat Clin Pract Nephrol"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.ki.5000438","volume":"70","author":"K.H. Han","year":"2006","unstructured":"Han KH, Kang YS, Han SY, et al.: Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006, 70:111\u2013120.","journal-title":"Kidney Int"},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"A.H. Meiracker van den","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, et al.: Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006, 24:2285\u20132292.","journal-title":"J Hypertens"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"G.P. Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, et al.: Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 2006, 48:232\u2013238.","journal-title":"Hypertension"},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"R.S. Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33\u201341.","journal-title":"N Engl J Med"},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"L.A. Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, et al.: Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295:2638\u20132645.","journal-title":"JAMA"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196511182732106","volume":"273","author":"J.W. Conn","year":"1965","unstructured":"Conn JW: Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965, 273:1135\u20131143.","journal-title":"N Engl J Med"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","volume":"150","author":"J.R. Sowers","year":"2009","unstructured":"Sowers JR, Whaley-Connell A, Epstein M: Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776\u2013783.","journal-title":"Ann Intern Med"},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A. Hirata","year":"2009","unstructured":"Hirata A, Maeda N, Hiuge A, et al.: Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009, 84:164\u2013172.","journal-title":"Cardiovasc Res"},{"key":"74_CR14","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"K.J. Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, et al.: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47:1936\u20131939.","journal-title":"Diabetologia"},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1523-1755.2004.00524.x","volume":"65","author":"N.K. Hollenberg","year":"2004","unstructured":"Hollenberg NK, Stevanovic R, Agarwal A, et al.: Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004, 65:1435\u20131439.","journal-title":"Kidney Int"},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.0000157408.43807.5a","volume":"45","author":"N. Kobayashi","year":"2005","unstructured":"Kobayashi N, Hara K, Tojo A, et al.: Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005, 45:538\u2013544.","journal-title":"Hypertension"},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","volume":"147","author":"C. Guo","year":"2006","unstructured":"Guo C, Martinez-Vasquez D, Mendez GP, et al.: Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006, 147:5363\u20135373.","journal-title":"Endocrinology"},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","volume":"33","author":"M. Nishimura","year":"1999","unstructured":"Nishimura M, Uzu T, Fujii T, et al.: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999, 33:261\u2013266.","journal-title":"Am J Kidney Dis"},{"key":"74_CR19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","volume":"93","author":"H.M. Siragy","year":"2008","unstructured":"Siragy HM, Xue C: Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008, 93:817\u2013824.","journal-title":"Exp Physiol"},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1210\/endo.137.10.8828470","volume":"137","author":"A. Sato","year":"1996","unstructured":"Sato A, Funder JW: High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996, 137:4145\u20134153.","journal-title":"Endocrinology"},{"key":"74_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A. Nishiyama","year":"2005","unstructured":"Nishiyama A, Yao L, Fan Y, et al.: Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 2005, 45:710\u2013716.","journal-title":"Hypertension"},{"key":"74_CR22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jsbmb.2005.03.005","volume":"96","author":"T. Nishikawa","year":"2005","unstructured":"Nishikawa T, Suematsu S, Saito J, et al.: Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 2005, 96:309\u2013316.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"74_CR23","doi-asserted-by":"crossref","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","volume":"286","author":"I. Juknevicius","year":"2004","unstructured":"Juknevicius I, Segal Y, Kren S, et al.: Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004, 286:F1059\u2013F1062.","journal-title":"Am J Physiol Renal Physiol"},{"key":"74_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfn448","volume":"24","author":"Y.S. Kang","year":"2009","unstructured":"Kang YS, Ko GJ, Lee MH, et al.: Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009, 24:73\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"74_CR25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","volume":"17","author":"S.Y. Han","year":"2006","unstructured":"Han SY, Kim CH, Kim HS, et al.: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362\u20131372.","journal-title":"J Am Soc Nephrol"},{"key":"74_CR26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","volume":"66","author":"G. Fujisawa","year":"2004","unstructured":"Fujisawa G, Okada K, Muto S, et al.: Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66:1493\u20131502.","journal-title":"Kidney Int"},{"key":"74_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1464-5491.2004.01295.x","volume":"22","author":"D.R. Cha","year":"2005","unstructured":"Cha DR, Kim IS, Kang YS, et al.: Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with type 2 diabetes mellitus. Diabet Med 2005, 22:14\u201320.","journal-title":"Diabet Med"},{"issue":"Suppl","key":"74_CR28","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.3346\/jkms.2009.24.S1.S195","volume":"24","author":"J.S. Han","year":"2009","unstructured":"Han JS, Choi BS, Yang CW, Kim YS: Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci 2009, 24(Suppl):S195\u2013S203.","journal-title":"J Korean Med Sci"},{"key":"74_CR29","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1053\/ajkd.2001.27422","volume":"38","author":"H. Yokoi","year":"2001","unstructured":"Yokoi H, Sugawara A, Mukoyama M, et al.: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. Am J Kidney Dis 2001, 38:S134\u2013S138.","journal-title":"Am J Kidney Dis"},{"key":"74_CR30","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/ndt\/gfm410","volume":"22","author":"S. Gauer","year":"2007","unstructured":"Gauer S, Segitz V, Goppelt-Struebe M: Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol Dial Transplant 2007, 22:3154\u20133159.","journal-title":"Nephrol Dial Transplant"},{"key":"74_CR31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/HJH.0b013e3280112ce5","volume":"25","author":"N. Heras de las","year":"2007","unstructured":"de las Heras N, Ruiz-Ortega M, Miana M, et al.: Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 2007, 25:629\u2013638.","journal-title":"J Hypertens"},{"key":"74_CR32","doi-asserted-by":"crossref","first-page":"F664","DOI":"10.1152\/ajprenal.00353.2002","volume":"285","author":"M.L. Gumz","year":"2003","unstructured":"Gumz ML, Popp MP, Wingo CS, Cain BD: Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. Am J Physiol Renal Physiol 2003, 285:F664\u2013F673.","journal-title":"Am J Physiol Renal Physiol"},{"key":"74_CR33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","volume":"58","author":"N.J. Brown","year":"2000","unstructured":"Brown NJ, Nakamura S, Ma L, et al.: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000, 58:1219\u20131227.","journal-title":"Kidney Int"},{"key":"74_CR34","doi-asserted-by":"crossref","first-page":"F1287","DOI":"10.1152\/ajprenal.00017.2008","volume":"294","author":"W. Huang","year":"2008","unstructured":"Huang W, Xu C, Kahng KW, et al.: Aldosterone and TGFbeta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008, 294:F1287\u2013F1295.","journal-title":"Am J Physiol Renal Physiol"},{"key":"74_CR35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5483\/BMBRep.2007.40.2.180","volume":"40","author":"J. Yuan","year":"2007","unstructured":"Yuan J, Jia R, Bao Y: Aldosterone up-regulates production of plasminogen activator inhibitor-1 by renal mesangial cells. J Biochem Mol Biol 2007, 40:180\u2013188.","journal-title":"J Biochem Mol Biol"},{"key":"74_CR36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1523-1755.2000.00214.x","volume":"58","author":"N. Banba","year":"2000","unstructured":"Banba N, Nakamura T, Matsumura M, et al.: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58:684\u2013690.","journal-title":"Kidney Int"},{"key":"74_CR37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.lfs.2007.06.025","volume":"81","author":"L. Lai","year":"2007","unstructured":"Lai L, Pen A, Hu Y, et al.: Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. Life Sci 2007, 81:570\u2013576.","journal-title":"Life Sci"},{"key":"74_CR38","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2005040390","volume":"16","author":"K. Miyata","year":"2005","unstructured":"Miyata K, Rahman M, Shokoji T, et al.: Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005, 16:2906\u20132912.","journal-title":"J Am Soc Nephrol"},{"key":"74_CR39","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1093\/ndt\/gfp182","volume":"24","author":"M.J. Hoven van den","year":"2009","unstructured":"van den Hoven MJ, Waanders F, Rops AL, et al.: Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009, 24:2637\u20132645.","journal-title":"Nephrol Dial Transplant"},{"key":"74_CR40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A. Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44\u201349.","journal-title":"Am J Hypertens"},{"key":"74_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","volume":"45","author":"S. Engeli","year":"2005","unstructured":"Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356\u2013362.","journal-title":"Hypertension"},{"key":"74_CR42","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S. Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116\u20132123.","journal-title":"Kidney Int"},{"key":"74_CR43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000111138.78714.1a","volume":"43","author":"S. Arima","year":"2004","unstructured":"Arima S, Kohagura K, Xu HL, et al.: Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004, 43:352\u2013357.","journal-title":"Hypertension"},{"key":"74_CR44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y. Furumatsu","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K, et al.: Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008, 31:59\u201367.","journal-title":"Hypertens Res"},{"key":"74_CR45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B. Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321.","journal-title":"N Engl J Med"},{"key":"74_CR46","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M. Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940\u2013951.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0074-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-009-0074-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-009-0074-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:21Z","timestamp":1559433381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-009-0074-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,29]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s11892-009-0074-x","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,29]]}}}